Literature DB >> 3946318

Vancomycin pharmacokinetics in small, seriously ill infants.

S H Naqvi, W J Keenan, R M Reichley, K P Fortune.   

Abstract

Twenty vancomycin pharmacokinetic studies were performed on 17 small infants who were receiving the antibiotic for treatment of documented infections. Fourteen patients were less than or equal to 41 weeks' postconception. In this group there was no statistical difference in mean elimination rate, volume of distribution, or clearance between neonates and infants 4 to 8 weeks of age. However, they had significantly lower clearance and prolonged mean beta-half-life than infants who were 3 to 6 months old (greater than 43 weeks' postconception). Vancomycin clearance was directly related to postconceptional age by linear regression analysis. beta-Half-life was influenced by the weight of the patient, volume of distribution, and gestational age. In view of the interpatient variability observed in the prematurely born infants, pharmacokinetic studies should be performed to determine the appropriate dose and intervals in vancomycin therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946318     DOI: 10.1001/archpedi.1986.02140160025021

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  15 in total

Review 1.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

3.  Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation.

Authors:  R D Amaker; J T DiPiro; J Bhatia
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 4.  Clinical Pharmacology Studies in Critically Ill Children.

Authors:  Nilay Thakkar; Sara Salerno; Christoph P Hornik; Daniel Gonzalez
Journal:  Pharm Res       Date:  2016-09-01       Impact factor: 4.200

5.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 6.  Antibiotics in neonatal infections: a review.

Authors:  V Fanos; A Dall'Agnola
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

7.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 8.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Dosage guidelines for the use of vancomycin based on its pharmacokinetics in infants.

Authors:  S M Lisby-Sutch; M C Nahata
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Vancomycin pharmacokinetics and dose recommendations for preterm infants.

Authors:  A James; G Koren; J Milliken; S Soldin; C Prober
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.